254 related articles for article (PubMed ID: 23659115)
1. Characteristics of medulloblastoma in children under age of three years.
Ryzhova MV; Zheludkova OG; Kumirova ÉV; Shishkina LV; Panina TN; Gorelyshev SK; Khukhlaeva EA; Mazerkina NA; Matuev KB; Medvedeva OA; Tarasova EM; Kholodov BV; Kapitul'skaia OIu
Zh Vopr Neirokhir Im N N Burdenko; 2013; 77(1):3-10; discussion 11. PubMed ID: 23659115
[TBL] [Abstract][Full Text] [Related]
2. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
Pfister S; Remke M; Benner A; Mendrzyk F; Toedt G; Felsberg J; Wittmann A; Devens F; Gerber NU; Joos S; Kulozik A; Reifenberger G; Rutkowski S; Wiestler OD; Radlwimmer B; Scheurlen W; Lichter P; Korshunov A
J Clin Oncol; 2009 Apr; 27(10):1627-36. PubMed ID: 19255330
[TBL] [Abstract][Full Text] [Related]
3. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients.
Lamont JM; McManamy CS; Pearson AD; Clifford SC; Ellison DW
Clin Cancer Res; 2004 Aug; 10(16):5482-93. PubMed ID: 15328187
[TBL] [Abstract][Full Text] [Related]
4. Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features.
Leonard JR; Cai DX; Rivet DJ; Kaufman BA; Park TS; Levy BK; Perry A
J Neurosurg; 2001 Jul; 95(1):82-8. PubMed ID: 11453402
[TBL] [Abstract][Full Text] [Related]
5. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
Korshunov A; Remke M; Kool M; Hielscher T; Northcott PA; Williamson D; Pfaff E; Witt H; Jones DT; Ryzhova M; Cho YJ; Wittmann A; Benner A; Weiss WA; von Deimling A; Scheurlen W; Kulozik AE; Clifford SC; Peter Collins V; Westermann F; Taylor MD; Lichter P; Pfister SM
Acta Neuropathol; 2012 Apr; 123(4):515-27. PubMed ID: 22160402
[TBL] [Abstract][Full Text] [Related]
6. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.
Korshunov A; Remke M; Werft W; Benner A; Ryzhova M; Witt H; Sturm D; Wittmann A; Schöttler A; Felsberg J; Reifenberger G; Rutkowski S; Scheurlen W; Kulozik AE; von Deimling A; Lichter P; Pfister SM
J Clin Oncol; 2010 Jun; 28(18):3054-60. PubMed ID: 20479417
[TBL] [Abstract][Full Text] [Related]
7. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.
Pfaff E; Remke M; Sturm D; Benner A; Witt H; Milde T; von Bueren AO; Wittmann A; Schöttler A; Jorch N; Graf N; Kulozik AE; Witt O; Scheurlen W; von Deimling A; Rutkowski S; Taylor MD; Tabori U; Lichter P; Korshunov A; Pfister SM
J Clin Oncol; 2010 Dec; 28(35):5188-96. PubMed ID: 21060032
[TBL] [Abstract][Full Text] [Related]
8. Nodule formation and desmoplasia in medulloblastomas-defining the nodular/desmoplastic variant and its biological behavior.
McManamy CS; Pears J; Weston CL; Hanzely Z; Ironside JW; Taylor RE; Grundy RG; Clifford SC; Ellison DW;
Brain Pathol; 2007 Apr; 17(2):151-64. PubMed ID: 17388946
[TBL] [Abstract][Full Text] [Related]
9. "Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study.
Brown HG; Kepner JL; Perlman EJ; Friedman HS; Strother DR; Duffner PK; Kun LE; Goldthwaite PT; Burger PC
J Neuropathol Exp Neurol; 2000 Oct; 59(10):857-65. PubMed ID: 11079775
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetic evaluation of isochromosome 17q in posterior fossa tumors of children and correlation with clinical outcome in medulloblastoma. Detection of a novel chromosomal abnormality.
DeChiara C; Borghese A; Fiorillo A; Genesio R; Conti A; D'Amore R; Pettinato G; Varone A; Maggi G
Childs Nerv Syst; 2002 Aug; 18(8):380-4. PubMed ID: 12192498
[TBL] [Abstract][Full Text] [Related]
11. Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors.
von Hoff K; Hartmann W; von Bueren AO; Gerber NU; Grotzer MA; Pietsch T; Rutkowski S
Pediatr Blood Cancer; 2010 Mar; 54(3):369-76. PubMed ID: 19908297
[TBL] [Abstract][Full Text] [Related]
12. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group.
Aldosari N; Bigner SH; Burger PC; Becker L; Kepner JL; Friedman HS; McLendon RE
Arch Pathol Lab Med; 2002 May; 126(5):540-4. PubMed ID: 11958658
[TBL] [Abstract][Full Text] [Related]
13. Accumulation of genomic aberrations during clinical progression of medulloblastoma.
Korshunov A; Benner A; Remke M; Lichter P; von Deimling A; Pfister S
Acta Neuropathol; 2008 Oct; 116(4):383-90. PubMed ID: 18704466
[TBL] [Abstract][Full Text] [Related]
14. Low-level copy gain versus amplification of myc oncogenes in medulloblastoma: utility in predicting prognosis and survival. Laboratory investigation.
Takei H; Nguyen Y; Mehta V; Chintagumpala M; Dauser RC; Adesina AM
J Neurosurg Pediatr; 2009 Jan; 3(1):61-5. PubMed ID: 19119907
[TBL] [Abstract][Full Text] [Related]
15. Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas.
Eberhart CG; Kratz JE; Schuster A; Goldthwaite P; Cohen KJ; Perlman EJ; Burger PC
Brain Pathol; 2002 Jan; 12(1):36-44. PubMed ID: 11770900
[TBL] [Abstract][Full Text] [Related]
16. Clinical and molecular stratification of disease risk in medulloblastoma.
Gilbertson R; Wickramasinghe C; Hernan R; Balaji V; Hunt D; Jones-Wallace D; Crolla J; Perry R; Lunec J; Pearson A; Ellison D
Br J Cancer; 2001 Sep; 85(5):705-12. PubMed ID: 11531256
[TBL] [Abstract][Full Text] [Related]
17. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.
Ellison DW; Kocak M; Dalton J; Megahed H; Lusher ME; Ryan SL; Zhao W; Nicholson SL; Taylor RE; Bailey S; Clifford SC
J Clin Oncol; 2011 Apr; 29(11):1400-7. PubMed ID: 20921458
[TBL] [Abstract][Full Text] [Related]
18. Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation.
Park AK; Lee SJ; Phi JH; Wang KC; Kim DG; Cho BK; Haberler C; Fattet S; Dufour C; Puget S; Sainte-Rose C; Bourdeaut F; Grill J; Delattre O; Kim SK; Park WY
Neuro Oncol; 2012 Feb; 14(2):203-14. PubMed ID: 22090452
[TBL] [Abstract][Full Text] [Related]
19. Clinical, pathological, and molecular data on desmoplastic/nodular medulloblastoma: case studies and a review of the literature.
Siegfried A; Bertozzi AI; Bourdeaut F; Sevely A; Loukh N; Grison C; Miquel C; Lafon D; Sevenet N; Pietsch T; Dufour C; Delisle MB
Clin Neuropathol; 2016; 35(3):106-13. PubMed ID: 26857864
[TBL] [Abstract][Full Text] [Related]
20. C-MYC expression in medulloblastoma and its prognostic value.
Herms J; Neidt I; Lüscher B; Sommer A; Schürmann P; Schröder T; Bergmann M; Wilken B; Probst-Cousin S; Hernáiz-Driever P; Behnke J; Hanefeld F; Pietsch T; Kretzschmar HA
Int J Cancer; 2000 Sep; 89(5):395-402. PubMed ID: 11008200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]